Impact of earlier versus later monitoring on disease progression and healthcare costs among patients with chronic myeloid leukemia in the United States-Reference-Cited by-同舟云学术

Impact of earlier versus later monitoring on disease progression and healthcare costs among patients with chronic myeloid leukemia in the United States

Published:2018-08-20 Issue:3 Volume:60 Page:668-674
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Jabbour Elias J.¹,Siegartel Lisa R.²,Lin Jay³,Lingohr-Smith Melissa³,Menges Brandy³,Makenbaeva Dinara²

Affiliation:

1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

2. Bristol-Myers Squibb, Princeton, NJ, USA;

3. Novosys Health, Green Brook, NJ, USA

Funder

Bristol-Myers Squibb

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1492124

Reference16 articles.

1. SEER Cancer Stat Facts: chronic myeloid leukemia [Internet]. Bethesda (MD): National Cancer Institute. Available from: https://seer.cancer.gov/statfacts/html/cmyl.html

2. National Comprehensive Cancer Network Guidelines. Chronic myeloid leukemia. v.4. Fort Washington PA): National Comprehensive Cancer Network; 2018.

3. Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia

4. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials

5. Evaluation of Long-Term Chronic Myeloid Leukemia Treatment Practices with Tyrosine Kinase Inhibitors in a National Cohort of Veterans

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maximizing the Value of Chronic Myeloid Leukemia Management Using Tyrosine Kinase Inhibitors in the USA: Potential Determinants and Consequences of Healthcare Resource Utilization and Costs, with Proposed Optimization Approaches;Clinical Drug Investigation;2024-01-05

2. Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia;Cancer;2019-04-11